Literature DB >> 23203941

Synthesis, characterization and pharmacodynamics of vitamin-B(12)-conjugated glucagon-like peptide-1.

Susan Clardy-James1, Oleg G Chepurny, Colin A Leech, George G Holz, Robert P Doyle.   

Abstract

Clearing the way: Glucagon-like peptide-1 (GLP-1) receptor agonists are proving a potent weapon in the treatment of type II diabetes. A new vitamin B(12)-GLP-1 conjugate is investigated and shown to have insulinotropic properties similar to the unmodified peptide. These results are critical to the exploitation of the vitamin B(12) oral uptake pathway for peptide delivery.
Copyright © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23203941      PMCID： PMC3771382          DOI： 10.1002/cmdc.201200461

Source DB:  PubMed          Journal:  ChemMedChem        ISSN： 1860-7179            Impact factor:   3.466


  28 in total

Review 1.  Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors.

Authors:  P L Brubaker; D J Drucker
Journal:  Recept Channels       Date:  2002

2.  Interplay of Ca2+ and cAMP signaling in the insulin-secreting MIN6 beta-cell line.

Authors:  Luis R Landa; Mark Harbeck; Kelly Kaihara; Oleg Chepurny; Kajorn Kitiphongspattana; Oliver Graf; Viacheslav O Nikolaev; Martin J Lohse; George G Holz; Michael W Roe
Journal:  J Biol Chem       Date:  2005-06-29       Impact factor: 5.157

Review 3.  Megalin- and cubilin-mediated endocytosis of protein-bound vitamins, lipids, and hormones in polarized epithelia.

Authors:  S K Moestrup; P J Verroust
Journal:  Annu Rev Nutr       Date:  2001       Impact factor: 11.848

4.  β-Arrestin1-mediated recruitment of c-Src underlies the proliferative action of glucagon-like peptide-1 in pancreatic β INS832/13 cells.

Authors:  Jason Talbot; Erik Joly; Marc Prentki; Jean Buteau
Journal:  Mol Cell Endocrinol       Date:  2012-08-24       Impact factor: 4.102

Review 5.  The physiology of glucagon-like peptide 1.

Authors:  Jens Juul Holst
Journal:  Physiol Rev       Date:  2007-10       Impact factor: 37.312

Review 6.  The biology of incretin hormones.

Authors:  Daniel J Drucker
Journal:  Cell Metab       Date:  2006-03       Impact factor: 27.287

7.  Glucagon-like peptide-1 7-36: a physiological incretin in man.

Authors:  B Kreymann; G Williams; M A Ghatei; S R Bloom
Journal:  Lancet       Date:  1987-12-05       Impact factor: 79.321

Review 8.  Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.

Authors:  Renee E Amori; Joseph Lau; Anastassios G Pittas
Journal:  JAMA       Date:  2007-07-11       Impact factor: 56.272

9.  Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats.

Authors:  Loredana Farilla; Hongxiang Hui; Cristina Bertolotto; Elizabeth Kang; Angela Bulotta; Umberto Di Mario; Riccardo Perfetti
Journal:  Endocrinology       Date:  2002-11       Impact factor: 4.736

10.  A novel cyclic adenosine monophosphate responsive luciferase reporter incorporating a nonpalindromic cyclic adenosine monophosphate response element provides optimal performance for use in G protein coupled receptor drug discovery efforts.

Authors:  Oleg G Chepurny; George G Holz
Journal:  J Biomol Screen       Date:  2007-05-16
View more
  10 in total

1.  Corrination of a GLP-1 Receptor Agonist for Glycemic Control without Emesis.

Authors:  Tito Borner; Jayme L Workinger; Ian C Tinsley; Samantha M Fortin; Lauren M Stein; Oleg G Chepurny; George G Holz; Aleksandra J Wierzba; Dorota Gryko; Ebba Nexø; Evan D Shaulson; Ankur Bamezai; Valentina A Rodriguez Da Silva; Bart C De Jonghe; Matthew R Hayes; Robert P Doyle
Journal:  Cell Rep       Date:  2020-06-16       Impact factor: 9.423

Review 2.  Strategic approaches to optimizing peptide ADME properties.

Authors:  Li Di
Journal:  AAPS J       Date:  2014-11-04       Impact factor: 4.009

Review 3.  New insights concerning the molecular basis for defective glucoregulation in soluble adenylyl cyclase knockout mice.

Authors:  George G Holz; Colin A Leech; Oleg G Chepurny
Journal:  Biochim Biophys Acta       Date:  2014-06-27

Review 4.  Controlled release of biologics for the treatment of type 2 diabetes.

Authors:  Caslin A Gilroy; Kelli M Luginbuhl; Ashutosh Chilkoti
Journal:  J Control Release       Date:  2015-12-02       Impact factor: 9.776

5.  Solution Structure and Constrained Molecular Dynamics Study of Vitamin B12 Conjugates of the Anorectic Peptide PYY(3-36).

Authors:  Kelly E Henry; Deborah J Kerwood; Damian G Allis; Jayme L Workinger; Ron L Bonaccorso; George G Holz; Christian L Roth; Jon Zubieta; Robert P Doyle
Journal:  ChemMedChem       Date:  2016-03-30       Impact factor: 3.466

6.  Enhanced Peptide Stability Against Protease Digestion Induced by Intrinsic Factor Binding of a Vitamin B12 Conjugate of Exendin-4.

Authors:  Ron L Bonaccorso; Oleg G Chepurny; Christoph Becker-Pauly; George G Holz; Robert P Doyle
Journal:  Mol Pharm       Date:  2015-08-11       Impact factor: 4.939

Review 7.  Regulation of glucose homeostasis by GLP-1.

Authors:  Prashant Nadkarni; Oleg G Chepurny; George G Holz
Journal:  Prog Mol Biol Transl Sci       Date:  2014       Impact factor: 3.622

8.  Can Bayliss and Starling gut hormones cure a worldwide pandemic?

Authors:  R V Scott; T M Tan; S R Bloom
Journal:  J Physiol       Date:  2014-09-12       Impact factor: 5.182

9.  Vitamin B12 conjugation of peptide-YY(3-36) decreases food intake compared to native peptide-YY(3-36) upon subcutaneous administration in male rats.

Authors:  Kelly E Henry; Clinton T Elfers; Rachael M Burke; Oleg G Chepurny; George G Holz; James E Blevins; Christian L Roth; Robert P Doyle
Journal:  Endocrinology       Date:  2015-02-06       Impact factor: 4.736

Review 10.  Glucagon-like peptide-1 in diabetes care: Can glycaemic control be achieved without nausea and vomiting?

Authors:  Tito Borner; Ian C Tinsley; Robert P Doyle; Matthew R Hayes; Bart C De Jonghe
Journal:  Br J Pharmacol       Date:  2021-09-14       Impact factor: 8.739
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.